There are lessons that are not taught in medical school. Students and trainees learn how to classify tumors according to their stage, their histology, their margins, the number of lymph nodes they’ve ...

The largest randomized trial of its kind to date found noninferior survival and better arm morbidity among patients with breast cancer who did not undergo completion axillary lymph node dissection.

Tafasitamab and lenalidomide are likely to be approved with R-CHOP for frontline DLBCL, but with bispecific antibodies on the horizon, the role of the combination is uncertain.